Clearing amyloid through the blood-brain barrier.
According to the amyloid hypothesis, accumulation of amyloid beta-peptide (A beta) in the brain is the primary pathogenic event in Alzheimer's disease (AD). Recent evidence indicates that A beta within the intravascular space is linked to A beta deposited in the brain suggesting that transport of A beta between the brain, blood and cerebrospinal fluid, and across the blood-brain barrier, regulates brain A beta. Thus, understanding A beta exchanges between brain and blood, and vice versa, and developing transport-based systemic A beta-lowering strategies may provide new important insights into pathogenesis and therapeutic control of AD.
Zlokovic
Berislav V
BV
Frank P. Smith Laboratories for Neuroscience, Department of Neurological Surgery, University of Rochester Medical Center, New York 14642, USA. berislav_zlokovic@urmc.rochester.edu
D000544:Alzheimer Disease / Q000378:metabolism* / Q000628:therapy; D000682:Amyloid / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D006801:Humans; D026502:LDL-Receptor Related Proteins / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism
D000682:Amyloid; D016229:Amyloid beta-Peptides; D026502:LDL-Receptor Related Proteins; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic